{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:55:46Z","timestamp":1793163346090,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Model-informed drug development (MIDD) is a framework that utilizes quantitative modeling and simulation methods to integrate nonclinical and clinical data, as well as prior knowledge, to inform drug development and regulatory decision-making. This scoping review examines the current MIDD landscape with a focus on pharmacometrics. It will clarify essential MIDD concepts and provide a taxonomy of terms. Additionally, it will evaluate the implications of the International Council for Harmonisation (ICH) M15 MIDD draft guidelines and summarize case studies that illustrate the use of MIDD in various drug development and lifecycle management scenarios. The diverse case studies span various therapeutic areas, small molecules, monoclonal antibodies, and long-acting injectable dosage forms. The ICH M15 MIDD guidelines aim to align the expectations of regulators and sponsors, support consistent regulatory decisions, and minimize errors in the acceptance of modeling and simulation. MIDD is a transformative and rigorous process that fosters collaboration between industry and regulatory agencies during drug development.MIDD has enabled accelerated approvals of drugs for pediatric conditions and rare diseases, where it can be difficult to recruit enough patients for efficacy studies. MIDD has contributed to the clinical pharmacology strategies that have successfully allowed dose extrapolation to related disease indications, dosage forms, and clinical populations without additional clinical trials.<\/jats:p>","DOI":"10.1007\/s10928-025-10005-8","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:34:09Z","timestamp":1760538849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Scoping review of the role of pharmacometrics in model-informed drug development"],"prefix":"10.1007","volume":"52","author":[{"given":"Amruta Gajanan","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euibeom","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"10005_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpt.3228","volume":"116","author":"R Madabushi","year":"2024","unstructured":"Madabushi R, Benjamin J, Zhu H, Zineh I (2024) The US food and drug administration\u2019s model-informed drug development meeting program: from pilot to pathway. Clin Pharmacol Ther 116:278\u2013281","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/cpt.1849","volume":"108","author":"R Madabushi","year":"2020","unstructured":"Madabushi R et al (2020) Role of guidance and policy in enhancing the impact of clinical Pharmacology in drug Development, Regulation, and use. Clin Pharmacol Ther 108:710\u2013715","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR3","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","volume":"39","author":"R Madabushi","year":"2022","unstructured":"Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H, Review (2022) Role of Model-Informed drug development approaches in the lifecycle of drug development and regulatory Decision-Making. Pharm Res 39:1669\u20131680","journal-title":"Pharm Res"},{"key":"10005_CR4","unstructured":"Anonymous (2024) General principles for model-informed drug development: M15. 19. International Council for Harmonisation (ICH), Geneva, Switzerland"},{"key":"10005_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19\u201332","journal-title":"Int J Soc Res Methodol"},{"key":"10005_CR6","doi-asserted-by":"crossref","unstructured":"Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z (2024) JBI manual for evidence synthesis. Joanna Briggs Institute (JBI), 2024","DOI":"10.46658\/JBIMES-24-01"},{"key":"10005_CR7","unstructured":"European Medicines Agency (2016) Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. (ed. Committee for Medicinal Products for Human Use (CHMP))"},{"key":"10005_CR8","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 1:e6","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10005_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:e38","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10005_CR10","unstructured":"European Medicines Agency\u00a0(2016) Guideline on reporting the results of population pharmacokinetic analyses. (ed. Committee for Medicinal Products for Human Use (CHMP))"},{"key":"10005_CR11","unstructured":"United States Food & Drug Administration (FDA)\u00a0(2022) Population pharmacokinetics guidance for industry. (ed. Center for Drug Evaluation and Research) 27\u00a0"},{"key":"10005_CR12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cpt.3525","volume":"117","author":"P Paul","year":"2025","unstructured":"Paul P, Colin PJ, Musuamba Tshinanu F, Versantvoort C, Manolis E, Blake K (2025) Current use of physiologically based pharmacokinetic modeling in new medicinal product approvals at EMA. Clin Pharmacol Ther 117:808\u2013817","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1602\/neurorx.1.3.307","volume":"1","author":"R Katz","year":"2004","unstructured":"Katz R (2004) FDA: evidentiary standards for drug development and approval. NeuroRx 1:307\u2013316","journal-title":"NeuroRx"},{"key":"10005_CR14","unstructured":"European Medicines Agency (2001) Points to consider on application with 1.meta-analyses, 2.one pivotal study. (ed. Committee for Medicinal Products for Human Use (CHMP)) 6\u00a0"},{"key":"10005_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/cts.12617","volume":"12","author":"AV Morant","year":"2019","unstructured":"Morant AV, Jagalski V, Vestergaard HT (2019) Characteristics of single pivotal trials supporting regulatory approvals of novel non-orphan, non-oncology drugs in the European union and United States from 2012\u20132016. Clin Transl Sci 12:361\u2013370","journal-title":"Clin Transl Sci"},{"key":"10005_CR16","unstructured":"United States Food & Drug Administration (FDA) (2019) Demonstrating substantial evidence of effectiveness for human drug and biological products. eds. Center for Drug Evaluation and Research and Center for Drug Evaluation and Research"},{"key":"10005_CR17","unstructured":"United States Food & Drug Administration (FDA) (1999) Guidance for industry: population pharmacokinetics. In: https:\/\/www.fda.gov\/media\/71364\/download"},{"key":"10005_CR18","unstructured":"Department of Health and Human Services (2003) Guidance for industry on exposure- response relationships\u2014study design, data analysis, and regulatory applications; Availability. Vol. 68 (ed. Food and Drug Administration) 24004. Federal Register, Washington"},{"key":"10005_CR19","unstructured":"Center for Drug Evaluation and Research (CDER) (2025) Division of pharmacometrics. (ed. Center for Drug Evaluation and Research (CDER)). U.S. Food and Drug Administration (FDA) Silver Spring"},{"key":"10005_CR20","doi-asserted-by":"publisher","first-page":"151S","DOI":"10.1177\/0091270010376977","volume":"50","author":"JV Gobburu","year":"2010","unstructured":"Gobburu JV (2010) Pharmacometrics 2020. J Clin Pharmacol 50:151S\u20137S","journal-title":"J Clin Pharmacol"},{"key":"10005_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bcp.12341","volume":"79","author":"H Kimko","year":"2015","unstructured":"Kimko H, Pinheiro J (2015) Model-based clinical drug development in the past, present and future: a commentary. Br J Clin Pharmacol 79:108\u2013116","journal-title":"Br J Clin Pharmacol"},{"key":"10005_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/psp4.12223","volume":"6","author":"E Manolis","year":"2017","unstructured":"Manolis E et al (2017) Commentary on the MID3 good practices paper. CPT Pharmacometrics Syst Pharmacol 6:416\u2013417","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10005_CR23","first-page":"93","volume":"5","author":"EFPIA MID3 Workgroup","year":"2016","unstructured":"EFPIA MID3 Workgroup (2016) Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT: Pharmacometrics & Systems Pharmacology 5:93\u2013122","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10005_CR24","first-page":"357","volume":"42","author":"S Barlas","year":"2017","unstructured":"Barlas S (2017) Drug companies breathe easier as PDUFA VI heads for approval. Pharm Ther (P T) 42:357","journal-title":"Pharm Ther (P T)"},{"key":"10005_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/psp4.12699","volume":"10","author":"LJ Lesko","year":"2021","unstructured":"Lesko LJ (2021) Perspective on model-informed drug development. CPT Pharmacometrics Syst Pharmacol 10:1127\u20131129","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10005_CR26","unstructured":"International Council for Harmonisation (ICH) Secretariat (2024) Progress on ICH Guideline Development and Important Revisions.\u00a0https:\/\/ich.org\/pressrelease\/press-release-ich-assembly-meeting-montreal-canada-november-2024 Accessed 28 Jan 2025"},{"key":"10005_CR27","unstructured":"Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research (2024) M15 general principles for model-informed drug development. U.S. Food and Drug Administration"},{"key":"10005_CR28","unstructured":"Anonymous (2018) V V 40 - Assessing credibility of computational modeling through verification and validaton: application to medical devices. 60 (American Society of Mechanical Engineers)"},{"key":"10005_CR29","first-page":"21","volume":"9","author":"C Kuemmel","year":"2020","unstructured":"Kuemmel C et al (2020) Consideration of a credibility assessment framework in model-informed drug development: potential application to physiologically-based pharmacokinetic modeling and simulation. CPT: Pharmacometrics & Systems Pharmacology 9:21\u201328","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10005_CR30","unstructured":"Center for Devices and Radiological Health\u00a0(2023) Assessing the Credibility of Computational Modeing and Simulation in Medical device Submissions: Guidance for Industry and Food and Drug Administration Staff. (eds. Laboratories, O.o.S.a.E. and (OSEL)) 42 (United States Food & Drug Administration (FDA)\u00a0"},{"key":"10005_CR31","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/cpdd.936","volume":"10","author":"E Felip","year":"2021","unstructured":"Felip E et al (2021) Results of a dose-finding phase 1b study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer. Clin Pharmacol Drug Dev 10:1142\u20131155","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10005_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/cpt.2823","volume":"113","author":"Z Xu","year":"2023","unstructured":"Xu Z et al (2023) Development of therapeutic proteins for a new subcutaneous route of administration after the establishment of intravenous dosages: a systematic review. Clin Pharmacol Ther 113:1011\u20131029","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR33","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/cpt.3178","volume":"115","author":"YC Wang","year":"2024","unstructured":"Wang YC et al (2024) Clinical pharmacology approaches to support approval of new routes of administration for therapeutic proteins. Clin Pharmacol Ther 115:440\u2013451","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/cpt.3133","volume":"115","author":"S Ait-Oudhia","year":"2024","unstructured":"Ait-Oudhia S et al (2024) Challenging the norm: a multidisciplinary perspective on intravenous to subcutaneous bridging strategies for biologics. Clin Pharmacol Ther 115:412\u2013421","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/psp4.13310","volume":"14","author":"P Chan","year":"2025","unstructured":"Chan P et al (2025) Population pharmacokinetics and Exposure-Response of subcutaneous Atezolizumab in patients with Non-Small cell lung cancer. CPT Pharmacometrics Syst Pharmacol 14:726\u2013737","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10005_CR36","unstructured":"United States Food & Drug Administration (FDA),(2024) Package insert: TECENTRIQ HYBREZATM (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761347s000lbl.pdf"},{"key":"10005_CR37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/annonc\/mdz037","volume":"30","author":"Y Bi","year":"2019","unstructured":"Bi Y (2019) Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Ann Oncol 30:644\u2013651","journal-title":"Ann Oncol"},{"key":"10005_CR38","unstructured":"United States Food & Drug Administration (FDA),(2022) Package insert: OPDIVO (nivolumab) injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125554s112lbl.pdf"},{"key":"10005_CR39","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","volume":"28","author":"X Zhao","year":"2017","unstructured":"Zhao X (2017) Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors. Ann Oncol 28:2002\u20132008","journal-title":"Ann Oncol"},{"key":"10005_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annonc.2019.10.015","volume":"31","author":"X Zhao","year":"2020","unstructured":"Zhao X (2020) Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types. Ann Oncol 31:302\u2013309","journal-title":"Ann Oncol"},{"key":"10005_CR41","volume-title":"FDA-2021-D-0691 (ed. Pharmacology, C.) 4","author":"United States Food & Drug Administration (FDA)","year":"2022","unstructured":"United States Food & Drug Administration (FDA) (2022) Pharmacokinetic-Based criteria for supporting alternative dosing regimens of programmed cell death Receptor-1 (PD-1) or programmed cell death-Ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry. Vol. FDA-2021-D-0691 (ed. Pharmacology, C.) 4. U.S. Department of Health and Human Services, Silver Spring, MD"},{"key":"10005_CR42","unstructured":"European Medicines Agency (2022) Model-based approaches for approval of alternative dosing regimens and routes of administration of (anti PD-1 and PD-L1) monoclonal antibodies. (ed. Committee for Medicinal Products for Human Use (CHMP))\u00a0"},{"key":"10005_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0177-2","volume":"4","author":"S Agrawal","year":"2016","unstructured":"Agrawal S, Feng Y, Roy A, Kollia G, Lestini B (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 4:72","journal-title":"J Immunother Cancer"},{"key":"10005_CR44","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0363-5","volume":"21","author":"Y Bi","year":"2019","unstructured":"Bi Y (2019) Model-informed drug development approach supporting approval of adalimumab (HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective. AAPS J 21:91","journal-title":"AAPS J"},{"key":"10005_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA et al (2022) Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386:24\u201334","journal-title":"N Engl J Med"},{"key":"10005_CR46","unstructured":"United States Food & Drug Administration (FDA)\u00a0(2003) Guidance for industry: exposure-response relationships \u2014 Study design, data analysis, and regulatory applications. (eds. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER)) 25\u00a0"},{"key":"10005_CR47","unstructured":"ICH Expert Working Group (2024) ICH harmonised guideline: pediatric extrapolation E11A. 30. International Council for harmonisation of technical requirements for pharmaceuticals for human use, Geneva, Switzerland"},{"key":"10005_CR48","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J (2022) Nivolumab plus relatlimab: first approval. Drugs 82:925\u2013931","journal-title":"Drugs"},{"key":"10005_CR49","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/psp4.13098","volume":"13","author":"Z Hu","year":"2024","unstructured":"Hu Z et al (2024) Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect. CPT Pharmacometrics Syst Pharmacol 13:476\u2013493","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10005_CR50","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-23-2396","volume":"30","author":"Y Zhao","year":"2024","unstructured":"Zhao Y et al (2024) Model-Informed clinical Pharmacology profile of a novel Fixed-Dose combination of nivolumab and relatlimab in adult and adolescent patients with solid tumors. Clin Cancer Res 30:3050\u20133058","journal-title":"Clin Cancer Res"},{"key":"10005_CR51","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11912-023-01406-4","volume":"25","author":"LJ Albrecht","year":"2023","unstructured":"Albrecht LJ, Livingstone E, Zimmer L, Schadendorf D (2023) The latest option: nivolumab and relatlimab in advanced melanoma. Curr Oncol Rep 25:647\u2013657","journal-title":"Curr Oncol Rep"},{"key":"10005_CR52","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/jcph.2429","volume":"64","author":"H Zhang","year":"2024","unstructured":"Zhang H et al (2024) Pediatric extrapolation approach for U.S. food and drug administration approval of Brexpiprazole in patients aged 13 to 17 years with schizophrenia. J Clin Pharmacol 64:771\u2013778","journal-title":"J Clin Pharmacol"},{"key":"10005_CR53","unstructured":"\u00a0United States Food & Drug Administration (FDA), (2021) NDA\/BLA multi-disciplinary review and evaluation of brexpiprazole. https:\/\/www.fda.gov\/media\/155985\/download"},{"key":"10005_CR54","first-page":"1448","volume":"13","author":"S Merali","year":"2024","unstructured":"Merali S et al (2024) Recommendation of Mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy. CPT: Pharmacometrics & Systems Pharmacology 13:1448\u20131461","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10005_CR55","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.123.066916","volume":"149","author":"KA McGurk","year":"2024","unstructured":"McGurk KA, Bilgehan N, Ware JS (2024) Pharmacogenetic influences over Mavacamten pharmacokinetics: considerations for the treatment of individuals with hypertrophic cardiomyopathy. Circulation 149:1786\u20131788","journal-title":"Circulation"},{"key":"10005_CR56","unstructured":"United States Food & Drug Administration (FDA),(2022) CAMZYOS(TM) (mavacamten) capsules for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214998s000lbl.pdf"},{"key":"10005_CR57","unstructured":"Buracchio T, Massie T, Cai X, Sharma V (2023) Tofersen. U.S. Food & Drug Administration"},{"key":"10005_CR58","unstructured":"United States Food & Drug Administration (FDA),(2023) QALSODY. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215887s000lbl.pdf"},{"key":"10005_CR59","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM et al (2022) Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 387:1099\u20131110","journal-title":"N Engl J Med"},{"key":"10005_CR60","unstructured":"United States Food & Drug Administration (FDA),(2022) Emergency Use Authorization (EUA) for Kineret (Anakinra). https:\/\/www.fda.gov\/media\/163546\/download"},{"key":"10005_CR61","doi-asserted-by":"publisher","DOI":"10.1177\/11772719211034685","volume":"16","author":"I Altintas","year":"2021","unstructured":"Altintas I et al (2021) SuPAR cut-offs for risk stratification in patients with symptoms of COVID-19. Biomark Insights 16:11772719211034685","journal-title":"Biomark Insights"},{"key":"10005_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101785","volume":"56","author":"K Akinosoglou","year":"2023","unstructured":"Akinosoglou K et al (2023) Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided Anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial. EClinicalMedicine 56:101785","journal-title":"EClinicalMedicine"},{"key":"10005_CR63","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.66125","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E (2021) An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. https:\/\/doi.org\/10.7554\/eLife.66125","journal-title":"Elife"},{"key":"10005_CR64","unstructured":"United States Food & Drug Administration (FDA),(2014) ABILIFY. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021436s038,021713s030,021729s022,021866s023lbl.pdf"},{"key":"10005_CR65","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.4088\/JCP.14m09741","volume":"76","author":"HY Meltzer","year":"2015","unstructured":"Meltzer HY et al (2015) A randomized, double-blind, placebo-controlled trial of Aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry 76:1085\u20131090","journal-title":"J Clin Psychiatry"},{"key":"10005_CR66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.64719\/pb.4361","volume":"47","author":"MT Morris","year":"2017","unstructured":"Morris MT, Tarpada SP (2017) Long-acting injectable Paliperidone palmitate: a review of efficacy and safety. Psychopharmacol Bull 47:42\u201352","journal-title":"Psychopharmacol Bull"},{"key":"10005_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13089","volume":"72","author":"A Russu","year":"2018","unstructured":"Russu A (2018) Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: practical guidance based on pharmacokinetic simulations. Int J Clin Pract 72:e13089","journal-title":"Int J Clin Pract"},{"key":"10005_CR68","unstructured":"Anonymous (2009) Clinical pharmacology and biopharmaceutics review (Paliperidone Palmitate). (ed. Center for Drug Evaluation and Research). U.S. Food & Drug Administration"},{"key":"10005_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3636","author":"V Sahasrabudhe","year":"2025","unstructured":"Sahasrabudhe V, Nicholas T, Nucci G, Musante CJ, Corrigan B (2025) Impact of model-informed drug development on drug development cycle times and clinical trial cost. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.3636","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR70","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/jcph.2418","volume":"64","author":"Y Yuan","year":"2024","unstructured":"Yuan Y et al (2024) Application of model-informed drug development in dose selection and optimization for SiRNA therapies. J Clin Pharmacol 64:799\u2013809","journal-title":"J Clin Pharmacol"},{"key":"10005_CR71","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/psp4.12597","volume":"10","author":"A Belov","year":"2021","unstructured":"Belov A, Schultz K, Forshee R, Tegenge MA (2021) Opportunities and challenges for applying model-informed drug development approaches to gene therapies. CPT Pharmacometrics Syst Pharmacol 10:286\u2013290","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10005_CR72","unstructured":"United States Food & Drug Administration (FDA)\u00a0(2025) Roadmap to Reducing Animal Testing in Preclinical Safety Studies. (ed. Pharmacology, C.) 11\u00a0"},{"key":"10005_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/cpt.3279","volume":"116","author":"W Anderson","year":"2024","unstructured":"Anderson W et al (2024) Unlocking the capabilities of large language models for accelerating drug development. Clin Pharmacol Ther 116:38\u201341","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR74","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-024-00969-9","volume":"26","author":"AK Ethirajulu","year":"2024","unstructured":"Ethirajulu AK, Sriramoju V, Bhat AG, Ramanathan M (2024) Evaluating alphafold for clinical pharmacology and pharmacogenetics: a case-study of Huntingtin variants linked to huntington\u2019s disease. AAPS J 26:106","journal-title":"AAPS J"},{"key":"10005_CR75","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/bcp.14801","volume":"88","author":"M McComb","year":"2022","unstructured":"McComb M, Bies R, Ramanathan M (2022) Machine learning in pharmacometrics: opportunities and challenges. Br J Clin Pharmacol 88:1482\u20131499","journal-title":"Br J Clin Pharmacol"},{"key":"10005_CR76","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/cpt.1746","volume":"107","author":"M McComb","year":"2020","unstructured":"McComb M, Ramanathan M (2020) Generalized pharmacometric modeling, a novel paradigm for integrating machine learning algorithms: a case study of metabolomic biomarkers. Clin Pharmacol Ther 107:1343\u20131351","journal-title":"Clin Pharmacol Ther"},{"key":"10005_CR77","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/bcp.15623","volume":"89","author":"R Nair","year":"2023","unstructured":"Nair R, Mohan DD, Frank S, Setlur S, Govindaraju V, Ramanathan M (2023) Generative adversarial networks for modelling clinical biomarker profiles with race\/ethnicity. Br J Clin Pharmacol 89:1588\u20131600","journal-title":"Br J Clin Pharmacol"},{"key":"10005_CR78","first-page":"111","volume":"50","author":"R Nair","year":"2023","unstructured":"Nair R, Mohan DD, Setlur S, Govindaraju V, Ramanathan M (2023) Generative models for age, race\/ethnicity, and disease state dependence of physiological determinants of drug dosing. J Pharmacokinet Pharmacodyn 50:111\u2013122","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10005_CR79","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10928-024-09921-y","volume":"51","author":"E Shin","year":"2024","unstructured":"Shin E, Yu Y, Bies RR, Ramanathan M (2024) Evaluation of ChatGPT and gemini large language models for pharmacometrics with NONMEM. J Pharmacokinet Pharmacodyn 51:187\u2013197","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10005_CR80","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00838-x","volume":"25","author":"JS Barrett","year":"2023","unstructured":"Barrett JS, Goyal RK, Gobburu J, Baran S, Varshney J (2023) An AI approach to generating MIDD assets across the drug development continuum. AAPS J 25:70","journal-title":"AAPS J"},{"key":"10005_CR81","unstructured":"United States Food & Drug Administration (FDA) (2025) Vol. FDA-2024-D-4689 (ed. Pharmacology, C.) 20. U.S. Department of Health and Human Services, Silver Spring, MD, Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products: draft guidance for industry and other interested parties"},{"key":"10005_CR82","unstructured":"United States Food & Drug Administration (FDA) (2025) FDA launches agency-wide AI tool to optimize performance for the American people. (ed. U.S. Department of Health and Human Services). U.S. Department of Health and Human Services, Rockville"},{"key":"10005_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.102207","volume":"32","author":"MS Alasmari","year":"2024","unstructured":"Alasmari MS (2024) Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: a primer for the MENA region. Saudi Pharm J 32:102207","journal-title":"Saudi Pharm J"},{"issue":"Suppl 1","key":"10005_CR84","first-page":"S60","volume":"61","author":"Y Bi","year":"2021","unstructured":"Bi Y et al (2021) Model-informed drug development in pediatric dose selection. J Clin Pharmacol 61(Suppl 1):S60\u2013S9","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"10005_CR85","first-page":"S104","volume":"59","author":"Y Bi","year":"2019","unstructured":"Bi Y (2019) Role of model-informed drug development in pediatric drug development, regulatory evaluation, and labeling. J Clin Pharmacol 59(Suppl 1):S104\u2013S11","journal-title":"J Clin Pharmacol"},{"key":"10005_CR86","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70272","volume":"18","author":"K Yang","year":"2025","unstructured":"Yang K, Gonzalez D, Woodhead JL, Bhargava P, Ramanathan M (2025) Leveraging in silico and artificial intelligence models to advance drug disposition and response predictions across the lifespan. Clin Transl Sci 18:e70272","journal-title":"Clin Transl Sci"},{"issue":"Suppl 2","key":"10005_CR87","first-page":"S27","volume":"62","author":"RJ Li","year":"2022","unstructured":"Li RJ (2022) Model-informed approach supporting drug development and regulatory evaluation for rare diseases. J Clin Pharmacol 62(Suppl 2):S27\u2013S37","journal-title":"J Clin Pharmacol"},{"key":"10005_CR88","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1517\/13543784.7.9.1483","volume":"7","author":"GL Southard","year":"1998","unstructured":"Southard GL, Dunn RL, Garrett S (1998) The drug delivery and biomaterial attributes of the ATRIGEL technology in the treatment of periodontal disease. Expert Opin Investig Drugs 7:1483\u20131491","journal-title":"Expert Opin Investig Drugs"},{"key":"10005_CR89","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/cpdd.928","volume":"10","author":"S Sharan","year":"2021","unstructured":"Sharan S, Fang L, Lukacova V, Chen X, Hooker AC, Karlsson MO (2021) Model-informed drug development for long-acting injectable products: summary of American college of clinical pharmacology symposium. Clin Pharmacol Drug Dev 10:220\u2013228","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10005_CR90","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev-pharmtox-031120-015212","volume":"61","author":"L Li","year":"2021","unstructured":"Li L et al (2021) Use of model-informed drug development to streamline development of long-acting products: can these successes be translated to long-acting hormonal contraceptives? Annu Rev Pharmacol Toxicol 61:745\u2013756","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10005_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000211","volume":"2","author":"L Burgert","year":"2022","unstructured":"Burgert L, Reiker T, Golumbeanu M, Mohrle JJ, Penny MA (2022) Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention. PLOS Glob Public Health 2:e0000211","journal-title":"PLOS Glob Public Health"},{"key":"10005_CR92","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10928-025-09973-8","volume":"52","author":"M Ramanathan","year":"2025","unstructured":"Ramanathan M, Krzyzanski W (2025) Diffusion dimensionality modeling of subcutaneous\/intramuscular absorption of antibodies and long-acting injectables. J Pharmacokinet Pharmacodyn 52:26","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10005_CR93","doi-asserted-by":"crossref","unstructured":"Duffull SB, Wright DFB, Zhu X, Liu X, Abulfathi A, Hishe H (2025) A pharmacometric workflow for resolving model instability in model use-reuse settings. CPT Pharmacometrics Syst Pharmacol","DOI":"10.1002\/psp4.70049"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-10005-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-10005-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-10005-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:28:22Z","timestamp":1781612902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-10005-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10005"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-10005-8","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amruta Gajanan Bhat has nothing to disclose.Euibeom Shin has nothing to disclose.Dr. Amit Roy is an employee of PumasAI.Dr. Murali Ramanathan is an employee of the University at Buffalo and received research funding from the National Multiple Sclerosis Society, the Department of Defense, the Gates Foundation, and the National Institute of Neurological Diseases and Stroke. He receives a royalty from a self-published textbook.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"See disclosure statement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial conflicts"}},{"value":"Artificial intelligence-enabled tools, such as Grammarly, Microsoft Word, and ChatGPT, were used to improve readability and language. Bibliographic tools, including Google and EndNote, helped curate references, add citations, and generate bibliographies. The generative AI features of graphics tools, like Adobe Illustrator, were utilized to create prototypes for some figures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of artificial intelligence"}}],"article-number":"56"}}